Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Trade Marks

Pearce IP BioBlast™: w/e 10 Apr 2020

by | Apr 13, 2020

Significant biosimilar activities this week include

March 20 | BiosanaPharma released the results of Ph I trials of BP001 (omalizumab), reporting comparability to Xolair®.

06 April 20 | The International Generic and Biosimilar Medicines Association (IGBA) called for urgent priority designation for medicines at custom controls for cargo and freight during the CoVid-19 pandemic. In particular, IGBA highlighted the need for ICU medicines and the goods needed to manufacture them to be moved at greater speeds through ‘green lanes’ .

08 April 20 | NeuClone Pharma announced it had completed monitoring visits and blood sampling for Ph I trials of NeuLara (ustekinumab).

08 April 20 | Pfizer announced FDA had approved Braftovi® (encorafenib) in combination with Erbitux® (cetuximab) for the treatment of BRAF600E-mutant metastatic colorectal cancer after prior therapy.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News